Lithium Carbonate in the Treatment of Graves’ Disease with ATD-Induced Hepatic Injury or Leukopenia
Table 1
Clinical and biochemical features of the study groups at baseline.
GD with hepatic injury
GD with leukopenia
Patients (male/female),
33 (5/28)
18 (3/15)
0.246
Age (month)
32.18 ± 15.21
35.25 ± 12.53
0.121
Duration (month)
12.34 ± 5.13
13.25 ± 6.51
0.435
Thyroid hormone
FT3 (pmol/L)
10.12 ± 4.58
10.86 ± 5.35
0.421
FT4 (pmol/L)
27.46 ± 8.94
28.52 ± 10.23
0.224
TSH (mIU/L)
0.11 ± 0.05
0.12 ± 0.04
0.532
Antibody
TRAb (U/L)
5.82 ± 7.11
6.13 ± 6.98
0.536
Positive TRAb (%)
30 (91)
17 (94)
0.452
Positive TPOAb (%)
11 (33)
7 (39)
0.251
Positive TGAb (%)
12 (36)
5 (28)
0.324
Liver function
ALT (U/L)
183.95 ± 124.58
19.64 ± 12.73
0.000
AST (U/L)
135.32 ± 131.46
18.27 ± 10.44
0.000
TBIL (μmol/L)
21.30 ± 11.69
12.38 ± 8.47
0.000
Blood cell count
WBC (×109/L)
6.49 ± 1.73
2.71 ± 0.58
0.000
N (×109/L)
3.23 ± 0.89
1.35 ± 0.42
0.000
Thyromegaly (%)
I
10 (30)
7 (39)
0.832
II
23 (70)
11 (61)
0.726
Used ATD (%)
MMI
27 (81)
15 (83)
0.321
PTU
6 (19)
3 (17)
0.234
Data were expressed as mean ± standard deviation or percentage of the total. FT4, free thyroxine; FT3, free triiodothyronine; TSH, Thyroid Stimulating Hormone; TRAb, thyrotropin receptor antibody; TgAb, thyroglobulin antibodies; TPOAb, thyroglobulin antibodies; ALT, aminotransferase; AST, aspartate aminotransferase; WBC, white blood cell; N, neutrophil.
